Trials:

1. Bowden CL, et al.; for the Divalproex Maintenance Study Group. Arch Gen Psychiatry 2000;57:481-9.
2. Bowden CL, et al.; for the Lamictal 606 Study group. Arch Gen Psychiatry 2003;60:392-400.
3. Burgess S, et al. Cochrane Database Syst Rev. 2001;(2):CD003013. Update: Cochrane Database Syst Rev.  2001;3:CD003013. 
4. Calabrese JR, et al.; for the Lamictal 605 Study Group. J Clin Psychiatry 2003;64:1013-24.
5. Coxhead N, et al. Acta Psychiatr Scand 1992;85:114-18.
6. Gelenberg AJ, et al. N Engl J Med 1989;321:1489-93. 
7. Goodwin F, et al. JAMA 2003;290:1467-73.
8. Greil W, Kleindienst N. Int Clin Psychopharmacol 1999;14:283-5. 
9. Hartong EG, et al.; and the LitCar Group. J Clin Psychiatry 2003;64:144-51.
10. Prien RF, et al. Arch Gen Psychiatry 1973;28:337-41. 
11. Prien RF, et al. Arch Gen Psychiatry 1973;29:420-5. 
12. Solomon DA, et al. J Clin Psychiatry 1997;58:95-9.

• WFSBP:
  Grunze, et al. World J Biol Psychiatry 2003; 4:5-13.
• Danish Guidelines:
  Licht, et al. Acta Psychiatr Scand 2003;108(S419):1-22. 
• Australian Guidelines:
  Mitchell PB, et al. Australasian Psychiatry 11(1):39-53.
• BAP Guidelines:
  Goodwin, et al. J Psychopharmacol 2003;17:149-73.
• APA Guidelines:
  Hirschfeld, et al. Am J Psychiatry 2002;159(4 Suppl):1-50.
• ICG Guidelines:
  J Clin Psychiatry 2004;65:(In press).